...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder.
【24h】

A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder.

机译：艾司西酞普兰和文拉法辛缓释剂在重度抑郁症治疗中的双盲比较。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Escitalopram is the most selective serotonin reuptake inhibitor (SRI) antidepressant available. Venlafaxine is a non-selective SRI that also inhibits noradrenergic re-uptake. This study compared escitalopram and venlafaxine extended release (XR) in depressed outpatients at the highest doses recommended in the United States. METHOD: In this randomized trial, patients (diagnosis of DSM-IV-defined major depressive disorder; baseline Hamilton Rating Scale for Depression score of >/= 20) received 1 week of single-blind placebo treatment, followed by 8 weeks of double-blind, fixed-dose treatment with either escitalopram or venlafaxine XR (rapidly titrated to 20 mg/day and 225 mg/day, respectively, in accordance with prescribing information). The primary efficacy variable was change from baseline to week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) total score. Data were collected from May to December 2002. RESULTS: Mean baseline MADRS scores for the escitalopram (N = 97) and venlafaxineXR (N = 98) groups were 30.7 and 30.0, respectively. There were no significant differences in measures of efficacy between the 2 antidepressants. Mean changes from baseline to endpoint in MADRS total score for escitalopram and venlafaxine XR were -15.9 and -13.6, respectively. Remission (MADRS score of /= 50% reduction from baseline MADRS score) rates for the escitalopram and venlafaxine XR groups were 58.8% and 48.0%, respectively. Tolerability measures favored escitalopram over venlafaxine XR treatment. The venlafaxine XR group had a higher incidence than the escitalopram group of treatment-emergent adverse events (85.0% vs. 68.4%) and discontinuation due to adverse events (16.0% vs. 4.1%; p <.01). CONCLUSION: Results of this study indicate that, when titrated rapidly to their maximum recommended doses, escitalopram is at least as effective as venlafaxine XR and significantly better tolerated. These results do notsupport the hypothesis that nonselective SRIs have greater efficacy than selective SRIs.
机译：背景：依西酞普兰是现有的最具选择性的5-羟色胺再摄取抑制剂（SRI）抗抑郁药。文拉法辛是一种非选择性SRI，也可抑制去甲肾上腺素再摄取。这项研究比较了美国推荐的最高剂量抑郁症门诊患者的依他普仑和文拉法辛缓释（XR）。方法：在该随机试验中，患者（诊断为DSM-IV定义的重度抑郁症;基线汉密尔顿抑郁量表评分为> / = 20）接受了1周的单盲安慰剂治疗，随后进行了8周的双盲安慰剂治疗。用依西酞普兰或文拉法辛XR盲目，固定剂量治疗（根据处方信息，分别迅速滴定至20 mg /天和225 mg /天）。主要疗效变量是蒙哥马利-阿斯伯格抑郁量表（MADRS）总分从基线到第8周的变化。收集2002年5月至2002年12月的数据。结果：依他普仑（N = 97）和venlafaxineXR（N = 98）组的平均基线MADRS评分分别为30.7和30.0。两种抗抑郁药的疗效指标无显着差异。依他普仑和文拉法辛XR的MADRS总评分从基线到终点的平均变化分别为-15.9和-13.6。艾司西酞普兰的缓解率（MADRS评分为 / = 50％）分别为58.8％和48.0％。耐受性措施优于依那普仑，而不是文拉法辛XR治疗。文拉法辛XR组发生的不良事件和因不良事件而终止治疗的发生率分别高于艾司西酞普兰组（85.0％对68.4％）（16.0％对4.1％; p <.01）。结论：这项研究的结果表明，当依他普仑快速滴定至最大推荐剂量时，其疗效至少与文拉法辛XR相同，并且耐受性明显更好。这些结果不支持非选择性SRI比选择性SRI具有更高功效的假设。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号